A Look At 3SBio (SEHK:1530) Valuation After Recent Share Price Strength

What recently stood out about 3SBio

3SBio (SEHK:1530) has caught investor attention after recent share price moves, with a 4.3% gain over the past day and a 6.5% rise over the past week, contrasting with weaker returns over the past month and past 3 months.

See our latest analysis for 3SBio.

Stepping back, the 1-day and 7-day share price returns of 4.26% and 6.52% sit against a weaker 30-day and 90-day share price picture. At the same time, the one year total shareholder return of roughly 3x suggests previous sentiment shifts have been very strong and current moves may reflect investors reassessing that earlier enthusiasm.

If 3SBio’s recent swings have you thinking about where else growth stories might emerge in healthcare, you may want to scan our focused list of 105 healthcare AI stocks for comparison.

With 3SBio trading at a reported discount to both analyst targets and intrinsic estimates despite softer recent returns, you have to ask yourself: is this an underappreciated healthcare name, or is the market already pricing in future growth?

Price-to-Earnings of 22.9x: Is it justified?

Using a simple P/E lens, 3SBio trades at 22.9x earnings, which screens as cheaper than both its industry and peer averages, even after the recent share price pullback to HK$24.5.

The P/E ratio tells you how much investors are currently paying for each dollar of earnings, which is a common shorthand for expectations around future profitability in biopharma. For 3SBio, the market is putting a lower P/E on the stock than the Asian Biotechs industry average of 41.8x and a peer average of 81.5x. Our estimated fair P/E sits at 18.8x, slightly below where the shares change hands today.

That combination sends a mixed signal. On one side, the discount to industry and peers suggests the market is not pricing 3SBio like the higher-rated names in its space. On the other, the current 22.9x is above the estimated fair P/E of 18.8x, which is a level the market could move towards if sentiment cools or earnings expectations reset.

Set against the Asian Biotechs average of 41.8x and a peer group closer to 81.5x, 3SBio’s 22.9x multiple looks materially lower, which some investors might read as restrained expectations compared with the sector.

Explore the SWS fair ratio for 3SBio

Result: Price-to-Earnings of 22.9x (ABOUT RIGHT)

However, recent annual revenue and net income declines, along with softer 30- and 90-day returns, could challenge the idea that the current P/E discount is a clear opportunity.

Find out about the key risks to this 3SBio narrative.

Another view: what the DCF says

While the P/E of 22.9x hints that 3SBio is not as highly rated as many peers, our DCF model paints a different picture. On that view, the shares at HK$24.5 trade well below an estimated future cash flow value of HK$54.23, which implies a sizeable valuation gap. Is the market too cautious here, or is the model too optimistic about those future cash flows?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out 3SBio for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 231 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own 3SBio Narrative

If you see the numbers differently or simply want to interpret the figures in your own way, you can build a personalised view of 3SBio in just a few minutes, starting with Do it your way.

A great starting point for your 3SBio research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you are weighing up your next move after looking at 3SBio, it can pay to line it up against other clear, data driven ideas from the Simply Wall St screener.

• Spot potential value opportunities early by scanning our 231 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect them yet.
• Focus on resilience first by filtering for companies in the 330 resilient stocks with low risk scores that score well on business stability and risk factors.
• Hunt for lesser known ideas with strong numbers using our screener containing 546 high quality undiscovered gems before they end up on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com